Press release
Long-Term Investors who lost money with the of Moderna, Inc. (NASDAQ: MRNA) should contact the Shareholders Foundation
An investigation on behalf of current long term investors in Moderna, Inc. (NASDAQ: MRNA) shares.
Investors who are current long term investors in Moderna, Inc. (NASDAQ: MRNA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: MRNA stocks follows a lawsuit filed against Moderna, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: MRNA stocks, concerns whether certain Moderna directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that mRNA-1345 was less effective than Defendants had led investors to believe, that accordingly, mRNA-1345's clinical and/or commercial prospects were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Moderna, Inc. (NASDAQ: MRNA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Long-Term Investors who lost money with the of Moderna, Inc. (NASDAQ: MRNA) should contact the Shareholders Foundation here
News-ID: 3872543 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of Tronox Holdings plc (N …
An investor, who purchased shares of Tronox Holdings plc (NYSE: TROX), filed a lawsuit over alleged violations of Federal Securities Laws by Tronox Holdings plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Tronox Holdings plc (NYSE: TROX) have certain options and for certain investors are short and strict deadlines running. Deadline: November 3, 2025. NYSE: TROX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation announced for Investors in Petco Health and Wellness Company, Inc. …
An investigation was announced for current long-term investors in shares of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) concerning potential breaches of fiduciary duties by certain directors of Petco Health and Wellness Company, Inc.
Investors who are current long term investors in Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation…
Investigation announced for Long-Term Investors in RxSight, Inc. (NASDAQ: RXST) …
An investigation was announced for current long-term investors in shares of RxSight, Inc. (NASDAQ: RXST) concerning potential breaches of fiduciary duties by certain directors of RxSight, Inc.
Investors who are current long term investors in RxSight, Inc. (NASDAQ: RXST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: RXST…
Tesla, Inc. (NASDAQ: TSLA) Investor Alert: Deadline in Lawsuit on October 3, 202 …
A deadline is coming up on October 3, 2025 in the lawsuit filed for certain investors of Tesla, Inc. (NASDAQ: TSLA) over alleged securities laws violations by Tesla, Inc.
Investors who purchased shares of Tesla, Inc. (NASDAQ: TSLA) have certain options and there are strict and short deadlines running. Deadline: October 3, 2025. Tesla, Inc. (NASDAQ: TSLA) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Moderna
mRNA Technology Market Is Booming So Rapidly | Pfizer, Moderna, BioNTech
HTF MI just released the Global mRNA technology Market Study, a comprehensive analysis of the market that spans more than 143+ pages and describes the product and industry scope as well as the market prognosis and status for 2025-2032. The marketization process is being accelerated by the market study's segmentation by important regions. The market is currently expanding its reach.
Major Giants in mRNA technology Market are:
Pfizer (USA), Moderna (USA), BioNTech…
U.S. Vaccine Market Set to Witness Robust Expansion - Pfizer, Moderna
U.S. Vaccine Market Insights
The U.S. Vaccine Market encompasses a broad portfolio of prophylactic and therapeutic vaccines designed to prevent infectious diseases such as influenza, pneumonia, HPV, and COVID-19. Products include traditional live-attenuated and inactivated formulations, conjugate vaccines, subunit vaccines, and next-generation mRNA platforms. Advantages of these offerings lie in their high efficacy, scalability, rapid production cycles, and ability to target emerging pathogens. Increasing collaborations between biotech firms and academic institutions,…
Messenger RNA Treatment Market Size Report 2032 | Translate Bio, AstraZeneca/Mod …
DelveInsight's "Messenger RNA Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Global Messenger RNA, historical and forecasted epidemiology as well as the Global Messenger RNA market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Messenger RNA Market Research Report
• The increase in Messenger RNA Market Size is a direct consequence of the increasing patient…
Nanostructured Drug Market Projected to Show Strong Growth|Celgene, Pfizer, Mode …
Advance Market Analytics published a new research publication on "Nanostructured Drug Market Insights, to 2030" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Nanostructured Drug market was mainly driven by the increasing R&D spending across the world.
Get Free Exclusive PDF Sample Copy of…
mRNA Drug Market Key Players - Moderna, Pfizer, Zydus Cadila, Fosun Pharma
Global mRNA Drug Market shows a quantitative fundamental market analysis to provide users with the most recent market dynamics, current market overview, and predicted market growth status for the forecast period of 2023-2029. The report provides a brief overview of the global mRNA Drug market globally to help build all existing as well as new market players with graphics, tables, pie charts based on past sizes and market forecast conditions.…
Vaccine Contract Manufacturing Market is Growing Rapidly with Catalent, Moderna
Contract manufacturing is a complex process involved in producing vaccine products. This type of production usually involves the manufacturing of vaccines in a single step. Contract manufacturers usually produce vaccines at their facilities; however, some contract manufacturers also service the field through the provision of workspace and by taking care of the closing storage and final disposition of finished products. Some contract manufacturers specialize in the manufacture of one or…
